Júlia Granell-Geli
Research Subjects
Júlia Granell-Geli has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Aina Teniente-Serra
Division of Immunology, LCMN Hospital Universitari Germans Trias i Pujol and Research Institute, Campus Can Ruti, 08916 Badalona, Spain
1 shared publication - Ares Sellés-Rius
Division of Immunology, LCMN Hospital Universitari Germans Trias i Pujol and Research Institute, Campus Can Ruti, 08916 Badalona, Spain
1 shared publication - Cristina Izquierdo-Gracia
Multiple Sclerosis Unit, Department of Neurosciences, Hospital Universitari Germans Trias i Pujol, 08916 Badalona, Spain
1 shared publication - Cristina Ramo-Tello
Hospital Germans Trias i Pujol, Badalona, Spain
1 shared publication - Ester Moral
Servicio de Neurología, Hospital Moises Broggi, Sant Joan Despí, Barcelona, Spain; Servicio de Neurología, Hospital General de L'Hospitalet, Hospitalet de Llobregat, Barcelona, Spain
1 shared publication - Eva María Martínez Cáceres
Division of Immunology, LCMN, Germans Trias i Pujol University Hospital and Research Institute, Badalona, Spain
1 shared publication
Latest Publications
- Open Access
- 10 December 2021
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 11 (12) , 1347
Assessing Blood-Based Biomarkers to Define a Therapeutic Window for Natalizumab
Natalizumab is a monoclonal antibody that binds CD49d. Although it is one of the most effective treatments for Relapsing-Remitting Multiple Sclerosis (RRMS), a dosing regimen has not been optimized for safety and efficacy in individual patients. We aimed to identify biomarkers to monitor Natalizumab treatment and to establish a personalized dose utilizing an ongoing longitudinal study in 29 RRMS patients under Natalizumab with standard interval dose (SD) of 300 mg/4wks or extended interval dose (EID) of 300 mg/6wks. Blood samples were analyzed by flow cytometry to determine CD49d saturation and expression in several T and B lymphocytes subpopulations. Each patient was analyzed at two different timepoints separated by 3 Natalizumab administrations. Natalizumab and sVCAM-1 levels in serum were also analyzed using ELISA. To determine the reproducibility of various markers, two different timepoints were compared and no significant differences were observed for CD49d expression nor for saturation; SD patients had higher saturation levels (~80%) than EID patients (~60%). A positive correlation exists between CD49d saturation and Natalizumab serum levels. CD49d expression and saturation are stable parameters that could be used as biomarkers in the immunomonitoring of Natalizumab treatment. Moreover, Natalizumab and sVCAM-1 serum levels could be used to optimize an individual’s dosing schedule.
- 10 December 2021
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 11 (12) , 1347
Open AccessAssessing Blood-Based Biomarkers to Define a Therapeutic Window for Natalizumab
Natalizumab is a monoclonal antibody that binds CD49d. Although it is one of the most effective treatments for Relapsing-Remitting Multiple Sclerosis (RRMS), a dosing regimen has not been optimized for safety and efficacy in individual patients. We aimed to identify biomarkers to monitor Natalizumab treatment and to establish a personalized dose utilizing an ongoing longitudinal study in 29 RRMS patients under Natalizumab with standard interval dose (SD) of 300 mg/4wks or extended interval dose (EID) of 300 mg/6wks. Blood samples were analyzed by flow cytometry to determine CD49d saturation and expression in several T and B lymphocytes subpopulations. Each patient was analyzed at two different timepoints separated by 3 Natalizumab administrations. Natalizumab and sVCAM-1 levels in serum were also analyzed using ELISA. To determine the reproducibility of various markers, two different timepoints were compared and no significant differences were observed for CD49d expression nor for saturation; SD patients had higher saturation levels (~80%) than EID patients (~60%). A positive correlation exists between CD49d saturation and Natalizumab serum levels. CD49d expression and saturation are stable parameters that could be used as biomarkers in the immunomonitoring of Natalizumab treatment. Moreover, Natalizumab and sVCAM-1 serum levels could be used to optimize an individual’s dosing schedule.